SINGAPORE, July 11 — For communities across Asia, the medicines that treat common infections are something many families take for granted. But behind the pharmacy counter, a quiet crisis is brewing. The global antibiotics market, valued at roughly $40.5 billion in 2022 according to market research firm Grand View Research, is projected to grow at a compound annual growth rate of 4.1% from 2023 to 2030.
Major pharmaceutical players include Pfizer, Merck, Johnson & Johnson, and GlaxoSmithKline. Yet for all its size, this market is failing at its most basic task: producing new drugs to fight superbugs.
The World Health Organization reported in 2021 that only 43 antibiotics were in clinical development, with few targeting the most resistant pathogens. That number is alarmingly low for a world facing what experts call antimicrobial resistance, or AMR. The central problem is money.
Developing a new antibiotic yields an estimated return on investment of about $50 million. Compare that to a cancer drug, where the return can reach $2.6 billion.
For pharmaceutical companies, the math is simple and stark. The U.S. introduced the PASTEUR Act in 2021 to create financial incentives for antibiotic development, but the legislation has not passed. Without new policy tools, the pipeline remains thin.
The economic consequences are already being felt. The U.S. Centers for Disease Control and Prevention estimated in 2019 that the economic burden of AMR in the United States alone reaches $55 billion annually, covering healthcare costs and lost productivity. For families, this translates into longer hospital stays, more expensive treatments, and the loss of effective first-line medicines for routine infections.
The long-term projections are sobering. A 2016 review led by economist Jim O’Neill estimated that without new antibiotics, the global economic impact could reach $100 trillion by 2050.
That figure captures lost productivity, increased healthcare spending, and the broader disruption to economies and communities. The disconnect between market size and innovation is striking. A $40.5 billion industry should be a powerhouse of research and development.
But the incentives are misaligned. Antibiotics are typically used for short courses, unlike chronic disease medications that generate steady, long-term revenue.
And new antibiotics are often held in reserve to preserve their effectiveness, further limiting sales. This is not a problem that any single country can solve alone. The PASTEUR Act in the U.S. represents one attempt to create a pull incentive — essentially paying companies for developing antibiotics regardless of how many doses are sold.
But its failure to pass so far underscores the political difficulty of addressing a slow-moving crisis. For now, the burden falls on public health systems, doctors trying to prescribe wisely, and families hoping the medicines they need will still work. The clock is ticking, and the pipeline remains thin.
